Paper Details

  1. Home
  2. Paper Details

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Author: , AttiaSteven, BauerSebastian, BeckerClaus, BlayJean-Yves, BoyeKjetil, ChiPing, DrutaMihaela, GelderblomHans, GeorgeSuzanne, GoldsteinDavid, HarrowBrooke, HeinrichMichael C, JonesRobin L, KangYoon-Koo, Le CesneAxel, RazakAlbiruni Abdul, ReichmannWilliam, Ruiz-SotoRodrigo, RutkowskiPiotr, SanchezCesar, SerranoCésar, ShermanMatthew L, SiontisBrittany L, SomaiahNeeta, SteeghsNeeltje, TrentJonathan, ZalcbergJohn R, von MehrenMargaret

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ripretinib provided better HRQoL compared to sunitinib in patients with advanced GIST previously treated with imatinib. Ripretinib may offer clinically meaningful benefit to these patients.
Paper Details　
Original Abstract of the Article :
PURPOSE: In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumour (GIST) previously treated with imatinib. We compared the impact of these treatments on health-related quality of life (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2023.113245

データ提供：米国国立医学図書館（NLM）

Ripretinib vs. Sunitinib: A Race to the Finish Line for GIST Patients

The world of cancer treatment is a competitive race, with researchers constantly striving to develop new drugs that offer better outcomes for patients. This study delves into the impact of two medications, ripretinib and sunitinib, on the quality of life of patients with advanced gastrointestinal stromal tumors (GIST). Both drugs have been shown to be effective in slowing tumor growth, but the researchers wanted to see how they compared in terms of patient experience.

Ripretinib: A Potential Winner in the Quality of Life Race

The study's results are promising, suggesting that ripretinib might be a more comfortable choice for patients with GIST. Compared to sunitinib, ripretinib was associated with better health-related quality of life (HRQoL) during the dosing period. Patients taking ripretinib reported fewer symptoms and side effects, leading to a greater number of days without experiencing treatment-related difficulties.

A Choice for Improved Quality of Life in Cancer Treatment

The findings of this study highlight the importance of considering a patient's overall well-being alongside the effectiveness of a treatment. Ripretinib offers the potential for a better quality of life during treatment, which is crucial for patients battling cancer. This research underscores the need for more comprehensive assessments of treatment outcomes, taking into account not just survival rates but also the impact on the patient's daily life.

Dr. Camel's Conclusion

It's encouraging to see research focusing on the patient's perspective, not just on the disease itself. While both drugs are effective in treating GIST, ripretinib appears to have a significant edge in terms of maintaining a good quality of life for the patient. This is a testament to the evolving field of cancer treatment, where the focus is shifting towards personalized care and maximizing the patient's well-being.

Date :
  1. Date Completed 2023-09-18
  2. Date Revised 2023-09-19
Further Info :

Pubmed ID

37598656

DOI: Digital Object Identifier

10.1016/j.ejca.2023.113245

Related Literature

Article Analysis
・Effects of ripretinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.